STOCK TITAN
  1. Home
  2. News
  3. SYBX

Synlogic, Inc. - SYBX STOCK NEWS

Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.

Synlogic, Inc. (Nasdaq: SYBX) is a clinical-stage biopharmaceutical company at the forefront of synthetic biology and microbiome research. The company is pioneering the development of Synthetic Biotics™, which are engineered probiotic bacteria designed to perform specific therapeutic functions. These innovative biotherapeutics target a range of metabolic and rare genetic diseases, addressing unmet medical needs.

Using its proprietary Synthetic Biotics™ platform, Synlogic engineers probiotics to correct metabolic dysfunctions linked to various diseases. These therapeutics are primarily delivered orally, acting from the gut microbiome to address systemic issues. The company’s lead programs include treatments for rare genetic metabolic disorders such as phenylketonuria (PKU) and homocystinuria (HCU). Synlogic's pipeline also targets conditions like enteric hyperoxaluria, gout, and cystinuria.

One of Synlogic's flagship projects, labafenogene marselecobac (SYNB1934), is currently in a global, pivotal Phase 3 study for PKU, known as Synpheny-3. Additional candidates, such as SYNB1353 for HCU, are also progressing through clinical stages. The company collaborates with notable partners including Roche for inflammatory bowel disease (IBD) research and Ginkgo Bioworks for synthetic biology advancements.

Synlogic's commitment to innovative medicine is further demonstrated by its recent achievements. In December 2023, the company announced that SYNB1353, a potential treatment for HCU, would be presented at the International Conference on Microbiome Engineering. Additionally, Synlogic secured a $1 million subcontract from the Air Force Research Lab to develop a manufacturing process for a potential live probiotic product, extending a project initiated in 2020.

The company’s approach leverages well-characterized probiotics, such as Escherichia coli Nissle 1917, ensuring consistency, safety, and non-colonizing properties, which simplify oral administration and storage. Synlogic continues to expand its pipeline and research capabilities, driving forward its mission to transform the care of serious diseases through groundbreaking synthetic biology technologies.

News

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) announces the acceptance of an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation. The poster presentation will be held at the International Conference on Microbiome Engineering 2023, showcasing the improvements of SYNB1353, an Engineered Bacteria for the Treatment of Homocystinuria, leading to increased In vitro and In vivo Degradation of Methionine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
none
-
News

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) reported a public offering of $21.0 million, extending cash runway into 2025. Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) for PKU. Milestone payment from Roche. Synpheny-3 trial progress supports enrollment completion in 2024, with top-line data in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.02%
Tags
earnings
-
News

Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration

Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The collaboration aims to address an undisclosed novel target in IBD, with Roche having the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
News

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Rhea-AI Summary
Synlogic, Inc. has closed its underwritten public offering, raising approximately $21.0 million. The offering consisted of 7,394,363 shares of common stock and accompanying warrants. The offering price per share was $2.84, with the warrants having an exercise price of $3.408 per share. The proceeds from the offering, along with existing cash and cash equivalents, are expected to fund operations until the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
offering
-
News

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Rhea-AI Summary
Synlogic, Inc. announces pricing of public offering, expecting $21.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.08%
Tags
offering
-
News

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Rhea-AI Summary
Synlogic, Inc. announces positive results from its Synpheny-1 Phase 2 study of labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU). The study shows dose-dependent reductions in plasma phenylalanine (Phe). Urgency to complete Synpheny-3 trial and advance potential new treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1032.62%
Tags
clinical trial
News

Synlogic Announces Reverse Stock Split

Rhea-AI Summary
Synlogic, Inc. will implement a 1-for-15 Reverse Stock Split to maintain its listing on Nasdaq. The split will reduce the number of outstanding shares from 69.0 million to 4.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags
none
-
News

Synlogic to Participate in Chardan’s Genetic Medicines Conference

Rhea-AI Summary
Synlogic, Inc. to participate in Chardan's Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences
-
News

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Rhea-AI Summary
Synlogic CEO honored as PharmaVoice 100 winner
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.81%
Tags
none
News

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Synlogic, Inc. reported financial results for Q2 2023 and provided an update on its pipeline programs. The company initiated a pivotal Phase 3 trial for labafenogene marselecobac as a potential treatment for PKU and received Fast Track designation from the FDA. They also announced the acceptance of the international non-proprietary name for the drug candidate. Synlogic had cash and cash equivalents of $46.3 million as of June 30, 2023, and expects to have sufficient cash to fund operations into the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
earnings

FAQ

What is the current stock price of Synlogic (SYBX)?

The current stock price of Synlogic (SYBX) is $1.42 as of December 20, 2024.

What is the market cap of Synlogic (SYBX)?

The market cap of Synlogic (SYBX) is approximately 16.3M.

What does Synlogic, Inc. specialize in?

Synlogic specializes in developing Synthetic Biotics™, engineered probiotic bacteria designed to treat various metabolic and rare genetic diseases.

What are Synthetic Biotics™?

Synthetic Biotics™ are engineered probiotics designed to perform specific therapeutic functions, correcting metabolic activities linked to diseases.

What is Synlogic’s lead program?

Synlogic's lead program is labafenogene marselecobac (SYNB1934), currently in Phase 3 trials for treating phenylketonuria (PKU).

What diseases are covered by Synlogic's pipeline?

Synlogic's pipeline includes treatments for PKU, homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria.

How does Synlogic deliver its Synthetic Biotics™?

Synlogic primarily delivers its Synthetic Biotics™ orally, where they act from the gut microbiome to correct systemic metabolic dysfunctions.

Who are Synlogic's research partners?

Synlogic collaborates with Roche on inflammatory bowel disease research and Ginkgo Bioworks on synthetic biology advancements.

What recent achievements has Synlogic announced?

Recent achievements include presenting SYNB1353 at a microbiome conference and securing a $1 million Air Force Research Lab subcontract.

What makes Synlogic's probiotics unique?

Synlogic's probiotics are well-characterized, non-colonizing, and reversible, ensuring safety and consistency while simplifying oral administration and storage.

What is SYNB1353 aimed at treating?

SYNB1353 is being developed as a potential treatment for homocystinuria (HCU).

Where can I find more information about Synlogic?

For more information, visit Synlogic’s website at www.synlogictx.com or follow them on Twitter, LinkedIn, Facebook, or Instagram.

Stock SYBX logo
Synlogic, Inc.

Nasdaq:SYBX

SYBX Rankings

#5392 Ranked by Market Cap
N/A Ranked by Dividends

SYBX Stock Data

16.32M
10.04M
14.19%
60.89%
0.45%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WINCHESTER